MedTrace Logo

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

NCT00861185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2011-07-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether 4 weeks of dosing with senicapoc alleviates exercise induced asthma symptoms.

Conditions

  • Exercise Induced Asthma

Interventions

DRUG

senicapoc

Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)

DRUG

Placebo

Placebo looks identical to active study medication and will be dosed according to the same dosing regimen

Sponsors & Collaborators

  • Icagen

    lead INDUSTRY

Principal Investigators

  • Jonathon Stocker, Ph.D. · Icagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-07-31
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861185 on ClinicalTrials.gov